TD Cowen raised the firm’s price target on TransMedics to $130 from $100 and keeps a Buy rating on the shares. The firm noted they raised their 2024 guidance as they have a multi-pronged plan to further propel growth, which includes three new clinical programs, one for OCS Lung and two for OCS Heart.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX: